Hematology-American Society of Hematology Education Program

Papers
(The H4-Index of Hematology-American Society of Hematology Education Program is 21. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
When should gene therapy be considered for transfusion-dependent β-thalassemia patients?64
Your chemo is no good here: management of high-risk MCL63
Inherited thrombophilia and recurrent miscarriage: is there a role for anticoagulation during pregnancy?56
Neurological manifestations of MGUS37
On the horizon: upcoming new agents for the management of ITP36
Anticoagulation at the end of life: whether, when, and how to treat36
Labor and delivery: DIC, HELLP, preeclampsia34
Mastocytosis demystified32
Hematopoietic cell transplantation for sickle cell disease: updates and future directions31
Inpatient recognition and management of HLH30
Bispecific antibody therapies27
Diagnosis and therapeutic decision-making for the neutropenic patient26
Recognizing, defining, and managing CAR-T hematologic toxicities25
Has PD-1 blockade changed the standard of care for cHL?25
Individualized patient care in nodular lymphocyte-predominant Hodgkin lymphoma24
Mutation- and MRD-informed treatment decisions for the transplant-eligible AML patient24
To consolidate or not to consolidate: the role of autologous stem cell transplantation in MCL23
T-cell–based therapies for treating relapsed or refractory mantle cell lymphoma23
Double-refractory Hodgkin lymphoma: tackling relapse after brentuximab vedotin and checkpoint inhibitors22
Divergent paths: management of early relapsed follicular lymphoma22
Logistics, risks, and benefits of automated red blood cell exchange for patients with sickle cell disease22
Hypoxia-inducible factor activators: a novel class of oral drugs for the treatment of anemia of chronic kidney disease21
New approaches to tackle cytopenic myelofibrosis21
0.025861024856567